Albendazole and Praziquantel: Review and Safety Monitoring in Korea

Sung-Tae Hong
Department of Parasitology and Tropical Medicine, Seoul National University College of Medicine, Seoul, Korea

Albendazole (ADZ) and praziquantel (PZQT) have been used as anthelmintics for over 30 years. Worldwide, hundreds of millions of tablets are administered to people and livestock every year. ADZ is poorly orally absorbed (<5%), and its uptake is enhanced by high-fat meals, while PZQT is well absorbed (>75%) and uptake is enhanced by carbohydrate-rich meals. Both ADZ and PZQT are safe, but not recommended for children <2 years or for women in the first trimester of pregnancy. Serious adverse events occur following high dose and prolonged administration of these drugs for treatment of echinococcosis or neurocysticercosis, especially in patients with poor liver function. The adverse events may be induced by the drugs, or by the dead worms themselves. The Korea Institute of Drug Safety & Risk Management monitors drug-related adverse events in Korea, and its database included 256 probable or possible ADZ-associated events and 108 PZQT-associated events between 2006 and 2015. Such low incidence rates in Korea are due to the low single dose treatments of ADZ, and the short-term use of PZQT. The number of serious adverse events due to drug interaction induced by ADZ and PZQT were six and two, respectively. We conclude that ADZ and PZQT are generally safe drugs, but they must be used with caution in people with poor liver function or those being comedicated for gastrointestinal reflux disease.

Key Words: Albendazole; Mebendazole; Praziquantel; Safety; Adverse Effects

Introduction

Human helminth infections, mainly due to soil-transmitted helminths (STHs), lymphatic filariasis (LF), and schistosomiasis (SCH) belong to the class of neglected tropical diseases (NTDs), and are major targets of global elimination programs. There are several NTDs against which the World Health Organization (WHO) and global funding organizations are implementing their elimination activities. However, the helminths responsible for the above three diseases are the major targets due to the number of individuals affected, their wide geographical distribution, and the potential for serious irreversible complications following infection. The main strategy of programs for the elimination of those NTDs is preventive chemotherapy (PC) employing anthelmintics, such as albendazole (ADZ) or mebendazole (MBDZ) for STHs, ADZ and diethylcarbamazine (DEC) and/or ivermectin (IVM) for LF and onchocerciasis, and praziquantel (PZQT) for SCH [1].
Albendazole

ADZ and MBDZ are the main anthelmintics used for global deworming of STHs. ADZ is also used during preventive chemotherapy (PC) to treat LF and onchocerciasis, as well as in PC of STHs. Because ADZ is a broad spectrum anthelmintic for treatment of various helminthiases as well as STHs, it is now used for chemotherapy of toxocariasis, gnathostomiasis, echinococcosis (cystic hydatid disease), taeniasis, and cysticercosis [1, 2]. The utility of ADZ for treatment of protozoan infections and as a candidate of anticancer chemotherapy is also being evaluated.

Table 1. Global status of donated anthelmintics distributed by WHO

| Year | No. of tablets/year (million) |
|------|-----------------------------|
|      | ADZ for LF | ADZ for STHs | MBDZ | PZQT |
| 2012 | 621        | 91           | 80   | 27   |
| 2013 | 630        | 144          | 94   | 53   |
| 2014 | 719        | 191          | 125  | 72   |
| 2015 | 648        | 244          | 135  | 107  |
| 2016 | 553        | 129          | 141  | 183  |
| 2017 | 613        | 314          | 206  | 151  |
| 2018 | 682 million | 288 million | 198 million | 97.5 million |

aPlanned number of treatments.

WHO, world health organization; ADZ, albendazole; LF, lymphatic filariasis; STH, soil-transmitted helminths; MBDZ, mebendazole; PZQT, praziquantel.

Source: WHO/NTD 2017 [2].
Patocytes were enlarged, and testicular hypoplasia was noted in mice receiving 400 mg/kg/day. The oral LD₅₀ differs according to the species; in mice it is >3,000 mg/kg, in rats 1,320–2,400 mg/kg, and in rabbits 500–1,250 mg/kg. The results of genotoxicity and carcinogenicity studies were negative, but fetal toxicity is known to occur in rats at ADZ doses > 7.5 mg/kg/day, in rabbits between 10 and 30 mg/kg/day, and in domesticated meat animals by 10 mg/kg/day [4]. Meat from ADZ-treated domesticated meat animals is deemed fit for human consumption after a short withholding period. However, ADZ-exposed meat is not recommended for children under 24 months.

On January 9, 2018, PubMed searches for ‘ADZ toxicity’ and ‘ADZ adverse effects’ retrieved 145 and 521 articles, respectively. Only a small portion of these articles were clinical reports, and the literature regarding the enormous volumes associated with global administration of ADZ tablets is scarce [2]. ADZ is used as a single agent to treat intestinal helminths, but is frequently combined with DEC and/or IVM for the treatment of LF or onchocerciasis. Its adverse effects are relatively rare and mild in the single agent context for treatment of STHs or other intestinal helminthiases [6, 7]. Biannual mass chemotherapy with a single dose of ADZ (400 mg) was associated with only a few cases complaining of short term abdominal discomfort from total 871 and 825 treated inhabitants in 2012 and 2013 respectively in Congo [6]. The frequency of adverse effects increases when ADZ is administered together with DEC and IVM [8]. More than half of medicated patients with LF complained, with symptoms of headache, joint pain, itching, abdominal pain, weakness, dizziness, and some objective findings such as fever, lymphadenitis, increased liver enzymes, proteinuria, hematuria, and transient lowering of blood pressure. These findings were elicited not only by ADZ, but also by combinations of anthelmintics or other drugs, and the consequential impacts of enhanced vermicidal activities. The dead bodies of filaria and microfilaria degenerate in the blood or lymph of infected hosts and, together with the drugs, this can contribute to the adverse effects reported [8].

3. Serious adverse effects

The frequency of serious adverse effects was highest when ADZ was administered at high doses for prolonged periods. The recommended dose of ADZ for the treatment of echinococcosis (hydatid cyst) in adults is 800 mg/day (two divided doses) for 1–2 months. One cohort study observing 35 children with abdominal echinococcosis in Argentina reported a mild increase in the level of liver enzymes and mild leukopenia induced by medication with ADZ 10–15 mg/kg/day for one month [9]. Cysts were inactivated in about half of the children following ADZ therapy, and the study concluded that the dose was optimal for children. However, more serious cases were reported following combined or prolonged medication, such as drug-induced psychosis by ADZ + IVM therapy [10], hemolytic anemia and kidney and brain injuries inducing acute renal failure by intravenous injection of ADZ [11], loss of body hair [12], and toxic hepatitis [13-15]. One 68-year-old man reportedly died due to ADZ-induced pancytopenia [16]. He had taken 400 mg of ADZ twice a day for 16 days to treat pulmonary echinococcosis, but was admitted to hospital due to sepsis. His bone marrow was seriously suppressed, leading to pancytopenia that was not successfully treated by hospital care, and the patient died due to severe bleeding. The patient had suffered from liver cirrhosis and poor liver function; the latter condition leads to reduced metabolism in the liver, and high levels of cir-
culating ADZ, which may inhibit the division of bone marrow hematopoietic cells. Thus, prolonged medication with ADZ requires monitoring of liver functions.

4. Anthelmintic resistance

The therapeutic failure of benzimidazole anthelmintics has been frequently reported in veterinary medicine. Because livestock are infected by various helminths, anthelmintic care is critical for their health and the economically viable production of meats or other veterinary products. ADZ resistance was noted in sheep infected by *Haemonchus contortus* [17]. ADZ resistance has not been confirmed in human parasites, but single nucleotide polymorphisms associated with benzimidazole resistance have been identified following genotyping of *Necator americanus* [18]. ADZ, fenbendazole, thiabendazole, MBDZ, oxfendazole, and ricobendazole have all been found to progressively lose their anthelmintic efficacy in livestock in Brazil [19]. This is perhaps not surprising, since ADZ and other benzimidazole derivatives have been used in huge amounts for more than 30 years, which may lead to the appearance of human-resident, drug-resistant helminths. Monitoring human parasitic helminths for the emergence of resistance thus remains a priority.

5. Anticancer efficacy

In addition to parasites, ADZ may preferentially kill cancer cells, since they can be viewed as a type of ‘parasite’ in the human body. One research article proposed ADZ as a new anticancer drug candidate, since it induces oxidative stress in tumor cells, promoting DNA fragmentation and triggering apoptosis [20]. Several nanoformulations that increase bioavailability have been investigated, and some are showing promising efficacy in the treatment of parasites and tumors [21, 22]. More rigorous studies are expected in this emerging area of ADZ use.

6. Drug safety in pregnancy

Single agent usage of ADZ is extremely safe for MDA of STHs and LF, and WHO has approved its use during pregnancy. One Korean report described ADZ medication of 124 women during the early stages of pregnancy, and did not detect significant hazardous outcomes [23]. One meta-analysis found no difference with regard to several clinical outcome parameters among pregnant women who were treated with ADZ during the second or third trimesters [24]. Summarizing the literature, it is generally accepted that ADZ is sufficiently safe to use for MDA in areas where there is endemic STHs and LF, but that prolonged medication is not acceptable in pregnant women.

**Mebendazole**

MBDZ is methyl 5-benzoyl-1H-benzimidazole-2-yl-carbamate, a broad spectrum anthelmintic for human and animals (Fig. 2). MBDZ is recommended for treatment of ascariasis, hookworm infection, and trichuriasis at a dosage of 100 mg twice daily for 3 consecutive days, and for enterobiasis at a single dose of 100 mg, with a second dose of 100 mg after 2–3 weeks. The solubility of MBDZ is limited, with oral absorption of 5–10% in humans and 1–2% after a high dose. Absorption of oral MBDZ is enhanced by eating high-fat meals. The poor solubility limits its use for hydatid cyst (echinococcosis) and other tissue helminthias. Most of the orally taken MBDZ is excreted via the feces in an unchanged form, whereas plasma MBDZ is metabolized by keto-reduction and decarbamylation of the imidazole ring [4]. The metabolites lose anthelmintic efficacy and are excreted in both the bile and urine. Individual variation of MBDZ metabolism is considerable, because of variable release and absorption rates. Co-administration of MBDZ with cimetidine leads to elevated plasma level in humans due to inhibition of first-pass cytochrome P450-mediated metabolism [4].

MBDZ was the first of several benzimidazole derivatives developed in the 1970s, whereas ADZ became more popular in 1980s. MBDZ is relatively non-toxic, but high doses may induce anemia and liver damage, as is observed with ADZ. MBDZ teratogenic in rats and mice at doses of 10 mg/kg/day, but this is not observed in other animals. MBDZ is contraindicated for pregnancy. With regard to its anthelmintic spectrum and adverse effect profile, MBDZ is almost identical to ADZ.

![Figure 2. Chemical structure of mebendazole. Source: Dayan, 2003](image-url)
Praziquantel

PZQT is a pyrazinoisoquinoline with the chemical name 2-cyclohexylcarbonyl-1,2,3,6,7,11b-hexahydropyrazino (2,1-a)isoquinolin-4-one (Fig. 3) [25]. PZQT is a broad spectrum anthelmintic in use since 1980, with activity against trematode or cestode helminthic infections of human and veterinary origin. Its bioactivity, pharmacokinetics, and clinical applications have already been discussed in detail in this journal [26].

1. Bioactivity

PZQT is a racemic mixture consisting of two enantiomers, R- and S-PZQT. An in vitro study showed that R-PZQT is essentially a vermicide agent with low toxicity, whereas S-PZQT has little anthelmintic activity, and induces toxicity [25]. The antischistosoma activity of R-PZQT is greater than that of S-PZQT, and its main metabolite, trans-4-OH-PZQT, is also effective against Schistosoma haematobium. The ED$_{50}$ of PZQT is 118.1 mg/kg, while that of R-PZQT is 24.7 mg/kg and S-PZQT 127.6 mg/kg. The antischistosoma activity of PZQT is greater against female worms than it is for males. Based on the bioactivity, a pediatric formulation is currently being developed [27].

Its mode of vermicidal action is uncertain, but PZQT rapidly causes paralytic muscular contraction by increased intracellular Ca$^{++}$ influx and tegumental disruption. It is hypothesized that the paralytic action of PZQT expels the worms from their primary habitat, after which the worms degenerate due to tegumental disruption [4, 26]. Intestinal absorption is good, reaching 75–100% of the oral dose, with a $t_{max}$ of 3 hours in humans. Carbohydrate-rich meals enhance PZQT absorption, but chloroquine, carbamazepine, and phenytoin may reduce its bioavailability. When coadministered with ADZ, the plasma level of PZQT is increased due to inhibition of P450 enzymes in the liver, as well as lowered metabolism. PZQT is metabolized by P450 enzymes in the liver to mono- or di-hydroxylated PZQT, and these metabolites may have weaker vermicidal activity. Clearance from the body is rapid, and occurs mainly through the urine. PZQT has no demonstrable genotoxicity, mutagenicity, carcinogenicity, or reproductive toxicity [4].

2. Target-dependent dose differences

PZQT is absorbed and cleared rapidly, as described above. The parental PZQT molecule is active, but following its metabolism, its activity drops; therefore, prolonged administration of high dose PZQT is required for tissue helminthiasis such as neurocysticercosis [26]. A single dose of 10 mg/kg PZQT is extremely effective for the treatment of intestinal trematodes or cestodes, because parental PZQT acts directly on worms in the intestine. However, a higher dose of 40 mg/kg is required for complete cure of schistosomiasis, because PZQT in the blood must act on the worm. Liver flukes (Clonorchis, Opisthorchis, Eurytrema, and Dicrocoelium) live in the intrahepatic or distal bile duct, and metabolized PZQT in the bile can expel the worms from their habitat. Thus, much higher PZQT concentration in the blood is required, and 3 doses of 25 mg/kg are recommended for treatment of liver fluke infections. Paragonimus adults reside in the middle of necrotic debris surrounded by a worm capsule, which is poorly vascularized. Therefore, a dosage of PZQT 25 mg/kg, three times per day, for 2–3 days is required to cure paragonimiasis. For neurocysticercosis, the recommended dose of PZQT is 25 mg/kg × 3/day, for 7–15 days. Here, a trade-off between dosage and side effects has to be reached. Specifically, a sufficiently high level of metabolized PZQT must cross the blood brain barrier in order to treat the disease, but prolonged administration of high dose PZQT may induce more adverse effects.

3. Toxicity and adverse events

A PubMed search using the keywords ‘praziquantel adverse effect’ on January 10, 2018 retrieved 73 articles. Most articles do not describe clinical toxicity or adverse reactions, but instead focus on anthelmintic effects. In general, the frequency of adverse reactions induced by PZQT is rare; toxicities are dose-dependent and can be reduced by taking the drug alongside meals.

Rim [28] published a monograph that summarized his studies on clonorchiasis, including the use of chemotherapy with PZQT. Most of the adverse effects associated with PZQT are mild and transient, and fall into two categorized into the two categories of digestive (abdominal discomfort or pain, vomit-
ing, and diarrhea) and neurological (headache, drowsiness, and sleepiness) [28].

Zwang and Olliaro [29] reviewed 828 studies, which included 47 related to the efficacy of PZQT (40 mg/kg single dose) for treatment of schistosomiasis in school children. The PZQT dosage led to a 70–80% cure rate and 80–90% egg reduction rate for *S. haematobium*, *S. mansoni*, and *S. japonicum* infections. The most common adverse effects were drowsiness (35.7%), abdominal pain (29.9%), headache (14.1%), fatigue (13.3%), nausea (11.9%), dizziness (11.6%), weakness (11.1%), diarrhea (10.8%), muscle pain (10.0%), vomiting (7.7%), allergy (6.5%), and itching (6.1%). The incidence of any adverse event was 55.5%, which is rather high [29].

Adverse effects after PZQT medication are produced by both drug toxicity and stimulation by dead worms in neurocysticercosis [30]. Most of the PZQT-treated patients with neurocysticercosis experienced adverse effects related to inflammation and increased intracranial pressure after death of the worms. Therefore, steroids and anticonvulsants are commonly coadministered with PZQT, although these drugs interact and can increase the frequency and severity of adverse effects. Indeed, one fatality due to increased intracranial pressure following PZQT treatment of neurocysticercosis has been reported [30].

Serious reactions are rare, but five cases of anaphylactic reaction have been reported [30, 31]. One 35-year-old Chinese man was cared at a hospital for anaphylaxis after taking PZQT to treat clonorchiasis in 2005 [31]. Lee et al. [32] reported a 54-year-old Korean woman who complained of skin rash, dyspnea, dizziness, and low blood pressure; this was the fifth case of PZQT anaphylaxis. Such an anaphylactic reaction has also been induced by antigens released from dead parasites after PZQT treatment in a murine *S. japonicum* infection model [33].

### Table 2. Comparison of basic bioavailability and safety of ADZ, MBDZ, and PZQT

| Items | ADZ for STHs or intestinal helminths | ADZ for tissue helminths | MBDZ | PZQT for intestinal helminths | PZQT for tissue helminths |
|-------|-------------------------------------|-------------------------|------|-------------------------------|--------------------------|
| Target parasites | *Ascaris*, hookworm, *Trichuris*, *Strongyloides*, *Enterobius* | *Trichinella*, *Toxocara*, *Echinococcus*, cysticercus, *Filaria*, *Onchocerca* | Intestinal trematodes or cestodes | *Clonorchis*/ *Opisthorchis*, *Paragonimus*, *Echinococcus*, neurocysticercosis |
| Dosage | 1 × 400 mg, 10 mg/kg for children | 2 × 400 mg/d ×30–60 days | 2 × 100 mg/d ×3 days | 1 × 10 mg/kg, 1 × 40 mg/kg for schistosomiasis | 3 × 25 mg/kg for liver fluke, 3 × 25 mg/kg/d ×7–14 days for echinococcosis/neurocysticercosis |
| Active form | ADZ sulfoxide | ADZ sulfoxide | Parental MBDZ | Parental PZQT | Parental PZQT |
| Oral absorption | <5%, enhanced with high fat meal | <5%, enhanced with high fat meal | <10%, enhanced with high fat meal | 75–100%, enhanced with carbohydrate rich meal | 75–100%, enhanced with carbohydrate rich meal |
| Limited use | <2 years Pregnancy 1st trimester | <2 years Pregnancy 1st trimester | <2 years Pregnancy | <2 years Pregnancy 1st trimester | <2 years Pregnancy 1st trimester |
| Frequency of AEs | Rare | Moderate | Rare | Rare | Frequent |
| Major AEs | Digestive symptoms | Bone marrow suppression, pancytopenia, hepatitis | Digestive symptoms, drowsiness, headache | Digestive symptoms, drowsiness, headache, Increased intracranial pressure |

ADZ, albendazole; MBDZ, mebendazole; PZQT, praziquantel; STHs, soil-transmitted helminths; AE, adverse effects
wide reports [34]. We downloaded adverse events associated with ADZ and PZQT reported during 2006–2015 in Korea from the KIDS database. A total of 856 reports were listed with ADZ or PZQT; many overlapped with multiple complaints, whereas 256 cases were specifically associated with ADZ and 108 were associated with PZQT (Table 3). Half of the cases were not drug-related or not suitable for evaluation due to limited information, and about half were regarded as probable or possible. Only one case could be verified as an individual that was treated with ADZ and PZQT.

1. Adverse events from probable or possible cases in KIDS

Most of the reported adverse effects were mild and transient, and subsided spontaneously and rapidly. The most frequent symptoms induced by both ADZ and PZQT were vomiting and nausea, but several other adverse effects that are often seen following anthelmintic treatment were also observed (Table 4). In Korea, ADZ is marketed freely and can be bought over the counter, whereas PZQT is accessed only under a doctor’s prescription. Currently, there is no MDA program in Korea. Based on production and marketing data generated by pharmaceutical companies, the estimated target population sizes for ADZ and PZQT treatment in Korea (2016) are 1,000,000 and 20,000, respectively. However, the number of people treated with anthelmintic medication is slowly decreasing every year. Based on the number of PZQT tablets produced by the Shin Poong Pharmaceutical Co. (Seoul, Korea), we estimate numbers of treated people in Korea (Table 5). The incidence of adverse effects should be evaluated based on numbers of consumers of the tablets. All of the adverse effects registered by the database of KIDS are described already in the literature.

### Table 3. Number of cases associated with ADZ- or PZQT-driven adverse events in Korea, 2006–2015

| Relevancy categories       | ADZ | PZQT |
|---------------------------|-----|------|
| Certain                   | 1   | 1    |
| Probable                  | 45  | 27   |
| Possible                  | 76  | 35   |
| Unlikely or not assessable| 134 | 45   |
| Total                     | 256 | 108  |

Source: Database from the Korea Institute of Drug Safety & Risk Management, 2016. ADZ, albendazole; PZQT, praziquantel.

### Table 4. Number of cases by reported adverse events by ADZ and PZQT in Korea, 2006–2015

| Adverse effects                          | No. of reported cases |
|------------------------------------------|-----------------------|
|                                          | ADZ       | PZQT       |
| Vomiting                                 | 18        | 13         |
| Nausea                                   | 9         | 11         |
| Indigestion                              | 3         | 0          |
| Diarrhea                                 | 7         | 3          |
| Constipation                             | 1         | 1          |
| Dizziness                                | 6         | 11         |
| Sleepiness                               | 0         | 2          |
| Headache                                 | 3         | 4          |
| Abdominal pain/discomfort                | 1         | 4          |
| Malaise                                  | 2         | 2          |
| Tremor                                   | 2         | 0          |
| Skin rash                                | 7         | 2          |
| Urticaria                                | 5         | 4          |
| Itching                                  | 3         | 2          |
| Alopecia                                 | 4         | 0          |
| Facial edema                             | 2         | 0          |
| Eyelid edema                             | 1         | 1          |
| Facial redness                           | 1         | 0          |
| Fever                                    | 7         | 0          |
| Chillness                                | 1         | 0          |
| Chest pain/tightness                     | 2         | 3          |
| Palpitation                              | 1         | 2          |
| Myocardial infarction                    | 2         | 0          |
| Difficult respiration                    | 1         | 0          |
| Shoulder pain                            | 0         | 1          |
| Abnormal liver function                  | 8         | 1          |
| Decreased blood pressure                 | 1         | 0          |
| Anaphylaxis                              | 1         | 0          |
| Leucopenia                               | 1         | 0          |
| Thrombocytopenia                         | 1         | 0          |
| Clotting delay                           | 1         | 0          |
| Anemia                                   | 1         | 0          |
| Eosinophilia                             | 6         | 0          |
| Hyperlipidemia                           | 2         | 0          |
| Hyperbilirubinemia                       | 1         | 0          |
| Voice change                             | 1         | 0          |
| Total                                    | 113       | 67         |

*Cases of probable or possible causal relations. ADZ, albendazole; PZQT, praziquantel. Source: Database from the Korea Institute of Drug Safety & Risk Management, 2016.
2. Serious adverse effects

Although rare, serious adverse effects were recorded by KIDS for ADZ (n = 6) and PZQT (n = 2); for these cases, medical care following hospital admission was required (Table 6). One (case 1 of ADZ) was a fatality due to heart failure after administration of ADZ. The affected individual was also taking several other drugs for gastroesophageal reflux disease (GERD), which may have interfered with ADZ metabolism and thereby engendered serious adverse effects. Cimetidine, which was included in the medication for GERD, is known to inhibit ADZ metabolism [5]. The exact cause of death was marked as “unclear.” However, an-other serious case involved coadministration of PZQT (case 2) with famotidine and other GERD medications. Thus, administration of ADZ or PZQT to patients who are taking cimetidine or similar proton pump inhibitors is not advised.

Conclusion

Both ADZ and PZQT are effective and safe anthelmintics. However, coadministration with cimetidine or similar proton pump inhibitors, or treatment of patients with poor liver, heart, or kidney function can lead to serious adverse effects. Clinicians should be advised not to prescribe ADZ or PZQT to individuals with any of the above complications. Both ADZ and PZQT are not recommended for children <2 years or for pregnant women in the first trimester. The frequency of adverse events is dose-dependent, and the effects are most often seen following prolonged usage at high doses in patients with echinococcosis or neurocysticercosis. Monitoring liver functions is recommended when prolonged medication with ADZ or PZQT is prescribed. Toxicity or adverse events can not only be induced by the drugs themselves, but also by molecules that are released from dead worms after medication.

Table 5. Estimated numbers\(^a\) of Korean people treated with PZQT tablets by year

| Year | No. of treated |
|------|---------------|
| 2012 | 53,000        |
| 2013 | 38,000        |
| 2014 | 33,000        |
| 2015 | 28,000        |
| 2016 | 20,000        |

\(^a\)Estimated by production of PZQT tablets by Shin Poong Pharmaceutical Co. PZQT, praziquantel.

Table 6. Cases with serious adverse effects reported to the Korea Institute of Drug Safety & Risk Management

| Cases (date of report) | Demography & clinical findings | Combined medications |
|------------------------|--------------------------------|----------------------|
| ADZ                    |                                |                      |
| Case 1 (Feb. 25, 2011) | 45/F, death by heart failure probably due to myocardial infarct. Treated for GERD | Enzyme preparations, propulsives, ambroxol, candesartan, cefazedone, cimetidine, ketoprofen, lorazepam, tramadol, magnesium compounds, metoclopramide, netilmicin, tulobuterol |
| Case 2 (2011)          | 47/F, nausea, vomiting, fever, elevated AST & ALT | Ciprofloxacin, doxycycline |
| Case 3 (Sep. 01, 2011) | 49/M, elevated AST & ALT | Abacavir, diosmectite, lamivudine, loperamide, pheniramine, protease inhibitors, pyridoxine (vit B6), sulfamethoxazole and trimethoprim, zolpidem |
| Case 4 (Jan 12, 2012)  | 57/M, skin rash, facial palsy, general weakness, hyperlipidemia | |
| Case 5 (2014)          | 47/M, skin rash, itching, tremor, low blood pressure, respiration difficulty by anaphylaxis | |
| Case 6 (Dec. 11, 2015) | 57/M, alopecia, diarrhea, fever, anemia, clotting disorder, thrombocytopenia, leukopenia | |
| PZQT                   |                                |                      |
| Case 1 (Apr. 25, 2012) | 75/F, dizziness, sleepiness | Drugs for GERD, acetylsalicylic acid, famotidine, olmesartan medoxomil, and diuretics |
| Case 2 (Sep. 27, 2010) | 53/M, decreased PT ratio | |

ADZ, albendazole; F, female; GERD, gastroesophageal reflux disease; AST, aspartate transaminase; ALT, alanine transaminase; M, male; PZQT, praziquantel.
Source: Database from the Korea Institute of Drug Safety & Risk Management, 2016.
**Funding**

The present work was partly supported by the Education and Research Encouraging Fund of the Seoul National University Hospital, 2017.

**Acknowledgement**

The author appreciates the data related to drug-related adverse events that was released by the Korea Institute of Drug Safety & Risk Management (KIDS), 2016. The primary data from KIDS were summarized ad analyzed by Dr. Hyun Beom Song, Department of Parasitology and Tropical Medicine, Seoul National University College of Medicine, Seoul, Korea.

**Conflicts of interest**

No conflicts of interest.

**ORCID**

Sung-Tae Hong  
https://orcid.org/0000-0002-0300-1944

**References**

1. Albonico M, Levecke B, LoVerde PT, Montresor A, Prichard R, Vercruyssse J, Webster JP. Monitoring the efficacy of drugs for neglected tropical diseases controlled by preventive chemotherapy. J Global Anti-microb Resist 2015;3:229-36.

2. World Health Organization (WHO). Update on the global status of the donation managed by WHO of the medicines for preventive chemotherapy (PC) 14 November 2017. Available at: http://www.who.int/neglected_diseases/preventive_chemotherapy/PC_medicines.pdf?ua=1 Accessed 28 December 2017.

3. Verrest L, Dorlo TPC. Lack of clinical pharmacokinetic studies to optimize the treatment of neglected tropical diseases: a systematic review. Clin Pharmacokinet 2017;56:583-606.

4. Dayan AD. Albendazole, mebendazole and praziquantel, Review of non-clinical toxicity and pharmacokinetics. Acta Trop 2003;86:141-59.

5. Nagy J, Schipper HG, Koopmans RP, Butter JJ, Van Boxtal CJ, Kager PA. Effect of grapefruit juice or cimetidine co-administration on albendazole bioavailability. Am J Trop Med Hyg 2002;66:260-3.

6. Pion SD, Chesnais CB, Bopda J, Louya F, Fischer PU, Majewski AC, Weil GJ, Boussinesq M, Missamou F. The impact of two semiannual treatments with albendazole alone on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in the Republic of Congo. Am J Trop Med Hyg 2015;92:959-66.

7. Moser W, Coulibaly JT, Ali SM, Amé SM, Amour AK, Yapi RB, Albonico M, Puchkov M, Huwyler J, Hattendorf J, Keiser J. Efficacy and safety of tribendimidine, tribendimidine plus ivermectin, tribendimidine plus oxantel pamoate, and albendazole plus oxantel pamoate against hookworm and concomitant soil-transmitted helminth infections in Tanzania and Côte d’Ivoire: a randomised, controlled, single-blind, non-inferiority trial. Lancet Infect Dis 2017;17:1162-71.

8. Thomsen EK, Sanuku N, Baëa M, Satofan S, Maki E, Lombo-re B, Schmidt MS, Siba PM, Weil GJ, Kazura JW, Fleckenstein LL, King CL. Efficacy, safety, and pharmacokinetics of coadministered diethylcarbamazine, albendazole, and ivermectin for treatment of bancroftian filariasis. Clin Infect Dis 2016;62:334-41.

9. Moroni S, Moscatelli G, Bournissen FG, González N, Ballering G, Freilij H, Salgueiro F, Althech J. Abdominal cystic echino-coccosis treated with albendazole. A Pediatric Cohort Study. PLoS One 2016;11:e0160472.

10. Mohapatra S, Sahoo AJ. Drug-induced psychosis associated with albendazole-ivermectin combination therapy in a 10-year-old child. J Child Adolesc Psychopjarmacol 2015;25:817-8.

11. Hogan J, Dehoux L, Niel O, Lensa N, Deschênes G, Dauger S. Hemolytic anemia and irreversible kidney and brain injuries after accidental intravenous injection of albendazole suspension in an infant. Clin Toxicol 2016;54:72-3.

12. Tas A, Köklü S, Celik H. Loss of body hair as a side effect of albendazole. Wien Klin Wochenschr 2012;124:220.

13. Choi GY, Yang HW, Cho SH, Kang DW, Go H, Lee WC, Lee YJ, Jung SH, Kim AN, Cha SW. Acute drug-induced hepatitis caused by albendazole. J Korean Med Sci 2008;23:903-5.

14. Marin Zuluaga JI, Marin Castro AE, Perez Cadavid JC, Restrepo Gutierrez JC. Albendazole-induced granulomatous hepatitis: a case report. J Med Case Rep 2013;7:201.

15. Amoruso C, Fuoti M, Miceli V, Zito E, Celano MR, De Giorgi A, Nebbia G. Acute hepatitis as a side effect of albendazole: a pediatric case. Pediatr Med Chir 2009;31:262-4.

16. Opatrny L, Prichard R, Snell L, Maclean JD. Death related to albendazole-induced pancytopenia: case report and review. Am J Trop Med Hyg 2005;72:291-4.

17. Borgsteede FH, Dercksen DD, Huijbers R. Doramectin and albendazole resistance in sheep in The Netherlands. Vet Par-
asitol 2007;144:180-3.

18. Rashwan N, Bourguinat C, Keller K, Gunawardena NK, de Silva N, Prichard R. Isothermal diagnostic assays for monitoring single nucleotide polymorphisms in *Necator americanus* associated with benzimidazole drug resistance. PLoS Negl Trop Dis 2016;10:e0005113.

19. Jaeger LH, Carvalho-Costa FA. Status of benzimidazole resistance in intestinal nematode populations of livestock in Brazil: a systematic review. BMC Vet Res 2017;13:358.

20. Castro LS, Kviecinski MR, Orique F, Parisotto EB, Grinevicius VM, Correia JF, Wilhelm Filho D, Pedrosa RC. Albenzazole as a promising molecule for tumor control. Redox Biol 2016;10:90-9.

21. Kang BS, Choi JS, Lee SE, Lee JK, Kim TH, Jang WS, Tunsirikongkon A, Kim JK, Park JS. Enhancing the *in vitro* anticancer activity of albendazole incorporated into chitosan-coated PLGA nanoparticles. Carbohydr Polym 2017;159:39-47.

22. Movahedi F, Li L, Gu W, Xu ZP. Nanoformulations of albendazole as effective anticancer and antiparasite agents. Nano Medicine (Lond) 2017;12:2555-74.

23. Choi JS, Han JY, Ahn HK, Ryu HM, Koren G. Foetal outcomes after exposure to albendazole in early pregnancy. J Obstet Gynaecol 2017;37:1108-11.

24. Salam RA, Haider BA, Humayun Q, Bhutta ZA. Effect of administration of anthelmintics for soil-transmitted helminths during pregnancy. Cochrane Database Syst Rev 2015:CD005547.

25. Sun Q, Mao R, Wang D, Hu C, Zheng Y, Sun D. The cytotoxicity study of praziquantel enantiomers. Drug Des Devel Ther 2016;10:2061-8.

26. Chai JY. Praziquantel treatment in trematode and cestode infections: an update. Infect Chemother 2013;45:32-43.

27. Kovac J, Vargas M, Keiser J. In vitro and in vivo activity of R- and S- praziquantel enantiomers and the main human metabolite trans-4-hydroxy-praziquantel against *Schistosoma haematobium*. Parasit Vectors 2017;10:365.

28. Rim HJ. The current pathobiology and chemotherapy of clonorchiasis. Kisaengchunghak Chapchi 1986;24 (Suppl):1-141.

29. Zwang J, Olliaro P. Efficacy and safety of praziquantel 40 mg/kg in preschool-aged and school-aged children: a meta-analysis. Parasites Vectors 2017;10:47.

30. Matthaiou DK, Panos G, Adamidi ES, Falagas ME. Albendazole versus praziquantel in the treatment of neurocysticercosis: a meta-analysis of comparative trials. PLoS Negl Trop Dis 2008;2:e194.

31. Shen C, Choi MH, Bae YM, Yu G, Wang S, Hong ST. A case of anaphylactic reaction to praziquantel treatment. Am J Trop Med Hyg 2017;96:603-5.

32. Lee JM, Lim HS, Hong ST. Hypersensitive reaction to praziquantel in a clonorchiasis patient. Korean J Parasitol 2011;49:273-5.

33. Matsumoto J. Adverse effects of praziquantel treatment of *Schistosoma japonicum* infection: involvement of host anaphylactic reactions induced by parasite antigen release. Int J Parasitol 2002;32:461-71.

34. Korea Institute of Drug Safety & Risk Management (KIDS). Available at: https://www.drugsafe.or.kr/en/index.do;sessionid=dXhaQ96oBqZW22vFNJe2WrzXyK1zJWb-bU2zuqhFyUklnYTz2MZRdWN7pYmKxgxWV.webint_2_servlet_engine1. Accessed 7 July 2016.